---
document_datetime: 2025-12-02 06:33:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lextemy.html
document_name: lextemy.html
version: success
processing_time: 0.1053396
conversion_datetime: 2025-12-24 01:03:56.621164
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lextemy

[RSS](/en/individual-human-medicine.xml/67435)

##### Withdrawn

This medicine's authorisation has been withdrawn

bevacizumab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lextemy](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 21 June 2021, the European Commission withdrew the marketing authorisation for Lextemy (bevacizumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Mylan IRE Healthcare Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Lextemy was granted marketing authorisation in the EU on 21 April 2021 for treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer, first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer, first line treatment of patients with advanced and/or metastatic renal cell cancer.

The marketing authorisation was initially valid for a 5-year period. Lextemy was a duplicate application to Abevmy, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Abevmy.

The European Public Assessment Report (EPAR) for Lextemy is updated to indicate that the marketing authorisation is no longer valid.

Lextemy : EPAR - Medicine overview

Reference Number: EMA/133097/2021

English (EN) (737.8 KB - PDF)

**First published:** 14/12/2021

[View](/en/documents/overview/lextemy-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-201)

български (BG) (827.52 KB - PDF)

**First published:**

14/12/2021

[View](/bg/documents/overview/lextemy-epar-medicine-overview_bg.pdf)

español (ES) (736.34 KB - PDF)

**First published:**

14/12/2021

[View](/es/documents/overview/lextemy-epar-medicine-overview_es.pdf)

čeština (CS) (808.36 KB - PDF)

**First published:**

14/12/2021

[View](/cs/documents/overview/lextemy-epar-medicine-overview_cs.pdf)

dansk (DA) (733.39 KB - PDF)

**First published:**

14/12/2021

[View](/da/documents/overview/lextemy-epar-medicine-overview_da.pdf)

Deutsch (DE) (739.84 KB - PDF)

**First published:**

14/12/2021

[View](/de/documents/overview/lextemy-epar-medicine-overview_de.pdf)

eesti keel (ET) (722.36 KB - PDF)

**First published:**

14/12/2021

[View](/et/documents/overview/lextemy-epar-medicine-overview_et.pdf)

ελληνικά (EL) (831.27 KB - PDF)

**First published:**

14/12/2021

[View](/el/documents/overview/lextemy-epar-medicine-overview_el.pdf)

français (FR) (738.22 KB - PDF)

**First published:**

14/12/2021

[View](/fr/documents/overview/lextemy-epar-medicine-overview_fr.pdf)

hrvatski (HR) (759.51 KB - PDF)

**First published:**

14/12/2021

[View](/hr/documents/overview/lextemy-epar-medicine-overview_hr.pdf)

italiano (IT) (734.5 KB - PDF)

**First published:**

14/12/2021

[View](/it/documents/overview/lextemy-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (1.42 MB - PDF)

**First published:**

14/12/2021

[View](/lv/documents/overview/lextemy-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (762.7 KB - PDF)

**First published:**

14/12/2021

[View](/lt/documents/overview/lextemy-epar-medicine-overview_lt.pdf)

magyar (HU) (837.62 KB - PDF)

**First published:**

14/12/2021

[View](/hu/documents/overview/lextemy-epar-medicine-overview_hu.pdf)

Malti (MT) (812.65 KB - PDF)

**First published:**

14/12/2021

[View](/mt/documents/overview/lextemy-epar-medicine-overview_mt.pdf)

Nederlands (NL) (735.84 KB - PDF)

**First published:**

14/12/2021

[View](/nl/documents/overview/lextemy-epar-medicine-overview_nl.pdf)

polski (PL) (809.77 KB - PDF)

**First published:**

14/12/2021

[View](/pl/documents/overview/lextemy-epar-medicine-overview_pl.pdf)

português (PT) (737.12 KB - PDF)

**First published:**

14/12/2021

[View](/pt/documents/overview/lextemy-epar-medicine-overview_pt.pdf)

română (RO) (762.04 KB - PDF)

**First published:**

14/12/2021

[View](/ro/documents/overview/lextemy-epar-medicine-overview_ro.pdf)

slovenčina (SK) (808.39 KB - PDF)

**First published:**

14/12/2021

[View](/sk/documents/overview/lextemy-epar-medicine-overview_sk.pdf)

slovenščina (SL) (802.42 KB - PDF)

**First published:**

14/12/2021

[View](/sl/documents/overview/lextemy-epar-medicine-overview_sl.pdf)

Suomi (FI) (732.68 KB - PDF)

**First published:**

14/12/2021

[View](/fi/documents/overview/lextemy-epar-medicine-overview_fi.pdf)

svenska (SV) (734.03 KB - PDF)

**First published:**

14/12/2021

[View](/sv/documents/overview/lextemy-epar-medicine-overview_sv.pdf)

## Product information

Lextemy : EPAR - Product Information

English (EN) (1.69 MB - PDF)

**First published:** 14/12/2021

[View](/en/documents/product-information/lextemy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-119)

български (BG) (3.49 MB - PDF)

**First published:**

14/12/2021

[View](/bg/documents/product-information/lextemy-epar-product-information_bg.pdf)

español (ES) (1.72 MB - PDF)

**First published:**

14/12/2021

[View](/es/documents/product-information/lextemy-epar-product-information_es.pdf)

čeština (CS) (2.9 MB - PDF)

**First published:**

14/12/2021

[View](/cs/documents/product-information/lextemy-epar-product-information_cs.pdf)

dansk (DA) (1.7 MB - PDF)

**First published:**

14/12/2021

[View](/da/documents/product-information/lextemy-epar-product-information_da.pdf)

Deutsch (DE) (1.85 MB - PDF)

**First published:**

14/12/2021

[View](/de/documents/product-information/lextemy-epar-product-information_de.pdf)

eesti keel (ET) (1.75 MB - PDF)

**First published:**

14/12/2021

[View](/et/documents/product-information/lextemy-epar-product-information_et.pdf)

ελληνικά (EL) (3.64 MB - PDF)

**First published:**

14/12/2021

[View](/el/documents/product-information/lextemy-epar-product-information_el.pdf)

français (FR) (1.83 MB - PDF)

**First published:**

14/12/2021

[View](/fr/documents/product-information/lextemy-epar-product-information_fr.pdf)

hrvatski (HR) (1.76 MB - PDF)

**First published:**

14/12/2021

[View](/hr/documents/product-information/lextemy-epar-product-information_hr.pdf)

íslenska (IS) (1.73 MB - PDF)

**First published:**

14/12/2021

[View](/is/documents/product-information/lextemy-epar-product-information_is.pdf)

italiano (IT) (1.75 MB - PDF)

**First published:**

14/12/2021

[View](/it/documents/product-information/lextemy-epar-product-information_it.pdf)

latviešu valoda (LV) (2.97 MB - PDF)

**First published:**

14/12/2021

[View](/lv/documents/product-information/lextemy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.81 MB - PDF)

**First published:**

14/12/2021

[View](/lt/documents/product-information/lextemy-epar-product-information_lt.pdf)

magyar (HU) (2.96 MB - PDF)

**First published:**

14/12/2021

[View](/hu/documents/product-information/lextemy-epar-product-information_hu.pdf)

Malti (MT) (3.03 MB - PDF)

**First published:**

14/12/2021

[View](/mt/documents/product-information/lextemy-epar-product-information_mt.pdf)

Nederlands (NL) (1.72 MB - PDF)

**First published:**

14/12/2021

[View](/nl/documents/product-information/lextemy-epar-product-information_nl.pdf)

norsk (NO) (1.67 MB - PDF)

**First published:**

14/12/2021

[View](/no/documents/product-information/lextemy-epar-product-information_no.pdf)

polski (PL) (2.99 MB - PDF)

**First published:**

14/12/2021

[View](/pl/documents/product-information/lextemy-epar-product-information_pl.pdf)

português (PT) (1.77 MB - PDF)

**First published:**

14/12/2021

[View](/pt/documents/product-information/lextemy-epar-product-information_pt.pdf)

română (RO) (1.79 MB - PDF)

**First published:**

14/12/2021

[View](/ro/documents/product-information/lextemy-epar-product-information_ro.pdf)

slovenčina (SK) (3.07 MB - PDF)

**First published:**

14/12/2021

[View](/sk/documents/product-information/lextemy-epar-product-information_sk.pdf)

slovenščina (SL) (2.91 MB - PDF)

**First published:**

14/12/2021

[View](/sl/documents/product-information/lextemy-epar-product-information_sl.pdf)

Suomi (FI) (695.48 KB - PDF)

**First published:**

14/12/2021

[View](/fi/documents/product-information/lextemy-epar-product-information_fi.pdf)

svenska (SV) (675.93 KB - PDF)

**First published:**

14/12/2021

[View](/sv/documents/product-information/lextemy-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lextemy : EPAR - All authorised presentations

English (EN) (588.96 KB - PDF)

**First published:** 14/12/2021

[View](/en/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-112)

български (BG) (652.99 KB - PDF)

**First published:**

14/12/2021

[View](/bg/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_bg.pdf)

español (ES) (588.36 KB - PDF)

**First published:**

14/12/2021

[View](/es/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (642.07 KB - PDF)

**First published:**

14/12/2021

[View](/cs/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (591.92 KB - PDF)

**First published:**

14/12/2021

[View](/da/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (589.09 KB - PDF)

**First published:**

14/12/2021

[View](/de/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (587.73 KB - PDF)

**First published:**

14/12/2021

[View](/et/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (649.48 KB - PDF)

**First published:**

14/12/2021

[View](/el/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_el.pdf)

français (FR) (603.46 KB - PDF)

**First published:**

14/12/2021

[View](/fr/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (621.04 KB - PDF)

**First published:**

14/12/2021

[View](/hr/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (589.72 KB - PDF)

**First published:**

14/12/2021

[View](/is/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (591.56 KB - PDF)

**First published:**

14/12/2021

[View](/it/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (640.4 KB - PDF)

**First published:**

14/12/2021

[View](/lv/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (624.27 KB - PDF)

**First published:**

14/12/2021

[View](/lt/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (620.83 KB - PDF)

**First published:**

14/12/2021

[View](/hu/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (643.86 KB - PDF)

**First published:**

14/12/2021

[View](/mt/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (590.31 KB - PDF)

**First published:**

14/12/2021

[View](/nl/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (590.2 KB - PDF)

**First published:**

14/12/2021

[View](/no/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_no.pdf)

polski (PL) (643.12 KB - PDF)

**First published:**

14/12/2021

[View](/pl/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_pl.pdf)

português (PT) (591.84 KB - PDF)

**First published:**

14/12/2021

[View](/pt/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_pt.pdf)

română (RO) (623.67 KB - PDF)

**First published:**

14/12/2021

[View](/ro/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (643.6 KB - PDF)

**First published:**

14/12/2021

[View](/sk/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (619.65 KB - PDF)

**First published:**

14/12/2021

[View](/sl/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (589.93 KB - PDF)

**First published:**

14/12/2021

[View](/fi/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (590.45 KB - PDF)

**First published:**

14/12/2021

[View](/sv/documents/all-authorised-presentations/lextemy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lextemy Active substance bevacizumab International non-proprietary name (INN) or common name bevacizumab Therapeutic area (MeSH)

- Colorectal Neoplasms
- Breast Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms

Anatomical therapeutic chemical (ATC) code L01XC07

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

## Authorisation details

EMA product number EMEA/H/C/005611

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Mylan IRE Healthcare Limited

Unit 35/36 Grange Parade

Opinion adopted 25/02/2021 Withdrawal of marketing authorisation 21/06/2021

## Assessment history

## Initial marketing authorisation documents

CHMP summary of positive opinion for Lextemy

Reference Number: EMA/CHMP/87640/2021

English (EN) (684.97 KB - PDF)

**First published:** 14/12/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lextemy_en.pdf-0)

Lextemy : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/680012/2021

English (EN) (7.07 MB - PDF)

**First published:** 14/12/2021

[View](/en/documents/assessment-report/lextemy-epar-public-assessment-report_en.pdf)

#### News on Lextemy

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021) 26/02/2021

**This page was last updated on** 24/02/2021

## Share this page

[Back to top](#main-content)